Claims

1. A method for immunizing a patient against influenza virus infection, comprising the steps of:(i) administering a dose of influenza virus vaccine in combination with a first adjuvant; and(ii) administering a further dose of influenza virus vaccine without that adjuvant.

2. The method of claim 1, wherein the further dose is administered by the same route as the first dose.

3. The method of claim 1, wherein the further dose is unadjuvanted.

4. The method of claim 1, wherein the further dose is adjuvanted with an adjuvant that is different from the first adjuvant.

5. A kit comprising:(i) a first influenza virus vaccine in combination with a first adjuvant; and(ii) a second influenza virus vaccine without that adjuvant.

6. (canceled)

7. A method for completing the immunization of a patient against influenza virus infection, wherein the patient has previously received a dose of influenza vims vaccine in combination with a first adjuvant, and wherein the method comprises the step of administering to that patient a further dose of influenza virus vaccine without that adjuvant.

8. The method of claim 7, wherein the further dose is administered by the same route as the previous dose.

9-10. (canceled)

11. The method of claim 1, wherein the vaccines include hemagglutinin at less than 15 μg per strain per vaccine.

12. The method of claim 1, wherein the influenza virus vaccines include an influenza virus antigen from a H1, H2, H3, H5, H7 or H9 influenza A vims subtype.

13. The method of claim 1, wherein the first adjuvant comprises an oil-in-water emulsion.

14. The method of claim 7 wherein the vaccines include hemagglutinin at less than 15 μg per strain per vaccine.

15. The method of claim 7 wherein the influenza virus vaccines include an influenza virus antigen from a H1, H2, H3, H5, H7 or H9 influenza A vims subtype.

16. The method of claim 7 wherein the first adjuvant comprises an oil-in-water emulsion.

17. The kit of claim 5 wherein the vaccines include hemagglutinin at less than 15 μg per strain per vaccine.

18. The kit of claim 5 wherein the influenza virus vaccines include an influenza virus antigen from a H1, H2, H3, H5, H7 or H9 influenza A vims subtype.

19. The kit of claim 5 wherein the first adjuvant comprises an oil-in-water emulsion.